Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Esche, C; Shurin, GV; Kirkwood, JM; Wang, GQ; Rabinowich, H; Pirtskhalaishvili, G; Shurin, MR
   Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition ofmitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis
   CLINICAL CANCER RESEARCH
   
   C. Esche et al., "Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition ofmitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis", CLIN CANC R, 7(3), 2001, pp. 974S-979S
2. Kirkwood, JM; Ibrahim, JG; Sosman, JA; Sondak, VK; Agarwala, SS; Ernstoff, MS; Rao, U
   High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
   JOURNAL OF CLINICAL ONCOLOGY
   
   J.M. Kirkwood et al., "High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801", J CL ONCOL, 19(9), 2001, pp. 2370-2380
3. Kirkwood, JM; Ibrahim, J; Lowson, DH; Aikins, MB; Agarwala, SS; Collins, K; Mascari, R; Morrissey, DM; Chapman, PB
   High-dose interferon alfa-2b does mot diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696
   JOURNAL OF CLINICAL ONCOLOGY
   
   J.M. Kirkwood et al., "High-dose interferon alfa-2b does mot diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696", J CL ONCOL, 19(5), 2001, pp. 1430-1436
4. Kirkwood, JM
   Adjuvant therapy of melanoma: At what cost? In reply
   JOURNAL OF CLINICAL ONCOLOGY
   
   J.M. Kirkwood, "Adjuvant therapy of melanoma: At what cost? In reply", J CL ONCOL, 19(4), 2001, pp. 1226-1228
5. Kilbridge, KL; Weeks, JC; Sober, AJ; Haluska, FG; Slingluff, CL; Atkins, MB; Sock, DE; Kirkwood, JM; Nease, RF
   Patient preferences for adjuvant interferon alfa-2b treatment
   JOURNAL OF CLINICAL ONCOLOGY
   
   K.L. Kilbridge et al., "Patient preferences for adjuvant interferon alfa-2b treatment", J CL ONCOL, 19(3), 2001, pp. 812-823
6. Kirkwood, JM; Ibrahim, J; Manola, J
   High-dose interferon versus GM2 vaccine in high-risk malignant melanoma - Reply
   JOURNAL OF CLINICAL ONCOLOGY
   
   J.M. Kirkwood et al., "High-dose interferon versus GM2 vaccine in high-risk malignant melanoma - Reply", J CL ONCOL, 19(23), 2001, pp. 4350-4350
7. van Londen, GJ; Mascarenhas, B; Kirkwood, JM
   Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI
   JOURNAL OF CLINICAL ONCOLOGY
   
   G.J. van Londen et al., "Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI", J CL ONCOL, 19(17), 2001, pp. 3794-3794
8. Balch, CM; Soong, SJ; Gershenwald, JE; Thompson, JF; Reintgen, DS; Cascinelli, N; Urist, M; McMasters, KM; Ross, MI; Kirkwood, JM; Atkins, MB; Thompson, JA; Coit, DG; Byrd, D; Desmond, R; Zhang, YT; Liu, PY; Lyman, GH; Morabito, A
   Prognostic factors analysis of 17,600 melanoma patients: Validation of theAmerican Joint Committee on Cancer melanoma staging system
   JOURNAL OF CLINICAL ONCOLOGY
   
   C.M. Balch et al., "Prognostic factors analysis of 17,600 melanoma patients: Validation of theAmerican Joint Committee on Cancer melanoma staging system", J CL ONCOL, 19(16), 2001, pp. 3622-3634
9. Balch, CM; Buzaid, AC; Soong, SJ; Atkins, MB; Cascinelli, N; Coit, DG; Fleming, ID; Gershenwald, JE; Houghton, A; Kirkwood, JM; McMasters, KM; Mihm, MF; Morton, DL; Reintgen, DS; Ross, MI; Sober, A; Thompson, JA; Thompson, JF
   Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma
   JOURNAL OF CLINICAL ONCOLOGY
   
   C.M. Balch et al., "Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma", J CL ONCOL, 19(16), 2001, pp. 3635-3648
10. Hillner, BE; Kirkwood, JM; Agarwala, SS
    Burden of illness associated with metastatic melanoma - An audit of 100 consecutive referral center cases
    CANCER
    
    B.E. Hillner et al., "Burden of illness associated with metastatic melanoma - An audit of 100 consecutive referral center cases", CANCER, 91(9), 2001, pp. 1814-1821
11. Agarwala, SS; Kirkwood, JM; Bryant, J
    Phase I, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer
    CYTOKINES CELLULAR & MOLECULAR THERAPY
    
    S.S. Agarwala et al., "Phase I, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer", CYTOK CELL, 6(4), 2000, pp. 171-176
12. Leaf, AN; Wolf, BC; Kirkwood, JM; Haselow, RE
    Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385)
    MEDICAL ONCOLOGY
    
    A.N. Leaf et al., "Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385)", MED ONCOL, 17(1), 2000, pp. 47-51
13. Lotze, MT; Shurin, M; Esche, C; Tahara, H; Storkus, W; Kirkwood, JM; Whiteside, TL; Elder, EM; Okada, H; Robbins, P
    Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    
    M.T. Lotze et al., "Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity", CA J SCI AM, 6, 2000, pp. S61-S66
14. Lawson, D; Kirkwood, JM
    Granulocyte-macrophage colony-stimulating factor: Another cytokine with adjuvant therapeutic benefit in melanoma?
    JOURNAL OF CLINICAL ONCOLOGY
    
    D. Lawson e J.M. Kirkwood, "Granulocyte-macrophage colony-stimulating factor: Another cytokine with adjuvant therapeutic benefit in melanoma?", J CL ONCOL, 18(8), 2000, pp. 1603-1605
15. Kirkwood, JM; Ibrahim, JG; Sondak, VK; Richards, J; Flaherty, LE; Ernstoff, MS; Smith, TJ; Rao, U; Steele, M; Blum, RH
    High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
    JOURNAL OF CLINICAL ONCOLOGY
    
    J.M. Kirkwood et al., "High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190", J CL ONCOL, 18(12), 2000, pp. 2444-2458
16. Edington, H; Agarwala, S; Kirkwood, JM
    Biologic therapy
    CLINICS IN PLASTIC SURGERY
    
    H. Edington et al., "Biologic therapy", CLIN PLAST, 27(4), 2000, pp. 643
17. Zarour, HM; Kirkwood, JM; Kierstead, LS; Herr, W; Brusic, V; Slingluff, CL; Sidney, J; Sette, A; Storkus, WJ
    Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitoperecognized by melanoma-reactive CD4(+) T cells
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    
    H.M. Zarour et al., "Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitoperecognized by melanoma-reactive CD4(+) T cells", P NAS US, 97(1), 2000, pp. 400-405
18. Zarour, HM; Storkus, WJ; Brusic, V; Williams, E; Kirkwood, JM
    NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+T cells
    CANCER RESEARCH
    
    H.M. Zarour et al., "NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+T cells", CANCER RES, 60(17), 2000, pp. 4946-4952
19. Balch, CM; Buzaid, AC; Atkins, MB; Cascinelli, N; Coit, DG; Fleming, ID; Houghton, A; Kirkwood, JM; Mihm, MF; Morton, DL; Reintgen, D; Ross, MI; Sober, A; Soong, SJ; Thompson, JA; Thompson, JF; Gershenwald, JE; McMasters, KM
    A new American Joint Committee on Cancer staging system for cutaneous melanoma
    CANCER
    
    C.M. Balch et al., "A new American Joint Committee on Cancer staging system for cutaneous melanoma", CANCER, 88(6), 2000, pp. 1484-1491
20. Kirkwood, JM; Mascari, RA; Edington, RD; Rabkin, MS; Day, RS; Whiteside, TL; Vlock, DR; Shipe-Spotloe, JM
    Analysis of therapeutic and immunologic effects of R-24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma
    CANCER
    
    J.M. Kirkwood et al., "Analysis of therapeutic and immunologic effects of R-24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma", CANCER, 88(12), 2000, pp. 2693-2702
21. Kirkwood, JM
    Adjuvant interferon in the treatment of melanoma
    BRITISH JOURNAL OF CANCER
    
    J.M. Kirkwood, "Adjuvant interferon in the treatment of melanoma", BR J CANC, 82(10), 2000, pp. 1755-1755
22. Agarawala, SS; Kirkwood, JM
    Adjuvant therapy of melanoma
    STRATEGIES IN ADJUVANT THERAPY
    
    S.S. Agarawala e J.M. Kirkwood, "Adjuvant therapy of melanoma", STRATEGIES IN ADJUVANT THERAPY, 2000, pp. 93-103
23. Agarwala, SS; Kirkwood, JM
    Melanoma - Immunotherapeutic approaches
    BIODRUGS
    
    S.S. Agarwala e J.M. Kirkwood, "Melanoma - Immunotherapeutic approaches", BIODRUGS, 12(3), 1999, pp. 193-208
24. Yang, P; Farkas, DL; Kirkwood, JM; Abernethy, JL; Edington, HD; Becker, D
    Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma
    MOLECULAR MEDICINE
    
    P. Yang et al., "Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma", MOL MED, 5(12), 1999, pp. 785-794
25. Kirkwood, JM; Farkas, DL; Chakraborty, A; Dyer, KF; Tweardy, DJ; Abernethy, JL; Edington, HD; Donnelly, SS; Becker, D
    Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions
    MOLECULAR MEDICINE
    
    J.M. Kirkwood et al., "Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions", MOL MED, 5(1), 1999, pp. 11-20
26. Chapman, PB; Einhorn, LH; Meyers, ML; Saxman, S; Destro, AN; Panageas, KS; Begg, CB; Agarwala, SS; Schuchter, LM; Ernstoff, MS; Houghton, AN; Kirkwood, JM
    Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma
    JOURNAL OF CLINICAL ONCOLOGY
    
    P.B. Chapman et al., "Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma", J CL ONCOL, 17(9), 1999, pp. 2745-2751
27. Tester, WJ; Kim, KM; Krigel, RL; Bonomi, PD; Glick, JH; Asbury, RF; Kirkwood, JM; Blum, RH; Schiller, JH
    A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer - An Eastern Cooperative Oncology Group study (PZ586)
    LUNG CANCER
    
    W.J. Tester et al., "A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer - An Eastern Cooperative Oncology Group study (PZ586)", LUNG CANC, 25(3), 1999, pp. 199-206
28. Agarwala, SS; Ferri, W; Gooding, W; Kirkwood, JM
    A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma
    CANCER
    
    S.S. Agarwala et al., "A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma", CANCER, 85(9), 1999, pp. 1979-1984
29. AGARWALA SS; KIRKWOOD JM
    ADJUVANT THERAPY OF MELANOMA
    Seminars in surgical oncology
    
    S.S. Agarwala e J.M. Kirkwood, "ADJUVANT THERAPY OF MELANOMA", Seminars in surgical oncology, 14(4), 1998, pp. 302-310
30. KIRKWOOD JM; BROWN IW
    EFFECT OF LIMB DAMAGE ON THE SURVIVAL AND BURIAL TIME OF DISCARDED SPANNER CRABS RANINA-RANINA (LINNAEUS)
    Marine and freshwater research
    
    J.M. Kirkwood e I.W. Brown, "EFFECT OF LIMB DAMAGE ON THE SURVIVAL AND BURIAL TIME OF DISCARDED SPANNER CRABS RANINA-RANINA (LINNAEUS)", Marine and freshwater research, 49(1), 1998, pp. 41-45
31. EGGERMONT AMM; KIRKWOOD JM
    MALIGNANT-MELANOMA - CURRENT CONTROVERSIES, FUTURE PERSPECTIVES - PROCEEDINGS OF A SYMPOSIUM HELD 27-28 FEBRUARY 1997, BARCELONA, SPAIN - INTRODUCTION
    European journal of cancer
    
    A.M.M. Eggermont e J.M. Kirkwood, "MALIGNANT-MELANOMA - CURRENT CONTROVERSIES, FUTURE PERSPECTIVES - PROCEEDINGS OF A SYMPOSIUM HELD 27-28 FEBRUARY 1997, BARCELONA, SPAIN - INTRODUCTION", European journal of cancer, 34, 1998, pp. 1-2
32. KIRKWOOD JM
    SYSTEMIC ADJUVANT TREATMENT OF HIGH-RISK MELANOMA - THE ROLE OF INTERFERON-ALPHA-2B AND OTHER IMMUNOTHERAPIES
    European journal of cancer
    
    J.M. Kirkwood, "SYSTEMIC ADJUVANT TREATMENT OF HIGH-RISK MELANOMA - THE ROLE OF INTERFERON-ALPHA-2B AND OTHER IMMUNOTHERAPIES", European journal of cancer, 34, 1998, pp. 12-17
33. AGARWALA SS; REYDERMAN A; STATKEVICH P; FRAASS U; LOOMBA A; STOVER LL; KIRKWOOD JM
    PHARMACOKINETIC STUDY OF TEMOZOLOMIDE PENETRATION INTO CSF IN A PATIENT WITH DURAL MELANOMA
    Annals of oncology
    
    S.S. Agarwala et al., "PHARMACOKINETIC STUDY OF TEMOZOLOMIDE PENETRATION INTO CSF IN A PATIENT WITH DURAL MELANOMA", Annals of oncology, 9, 1998, pp. 659-659
34. AGARWALA SS; KIRKWOOD JM
    ADJUVANT INTERFERON TREATMENT FOR MELANOMA
    Hematology/oncology clinics of North America
    
    S.S. Agarwala e J.M. Kirkwood, "ADJUVANT INTERFERON TREATMENT FOR MELANOMA", Hematology/oncology clinics of North America, 12(4), 1998, pp. 823
35. RANIERI E; GESUALDO L; HERR W; GAMBOTTO A; LOGAN T; ZAROUR H; KIRKWOOD JM; STORKUS WJ
    DC-BASED IMMUNIZING STRATEGIES TO PROMOTE ANTIRENAL CANCER T-CELL RESPONSE
    Journal of leukocyte biology
    
    E. Ranieri et al., "DC-BASED IMMUNIZING STRATEGIES TO PROMOTE ANTIRENAL CANCER T-CELL RESPONSE", Journal of leukocyte biology, 1998, pp. 33-33
36. FALKSON CI; IBRAHIM J; KIRKWOOD JM; COATES AS; ATKINS MB; BLUM RH
    PHASE-III TRIAL OF DACARBAZINE VERSUS DACARBAZINE WITH INTERFERON-ALPHA-2B VERSUS DACARBAZINE WITH TAMOXIFEN VERSUS DACARBAZINE WITH INTERFERON-ALPHA-2B AND TAMOXIFEN IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY
    Journal of clinical oncology
    
    C.I. Falkson et al., "PHASE-III TRIAL OF DACARBAZINE VERSUS DACARBAZINE WITH INTERFERON-ALPHA-2B VERSUS DACARBAZINE WITH TAMOXIFEN VERSUS DACARBAZINE WITH INTERFERON-ALPHA-2B AND TAMOXIFEN IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY", Journal of clinical oncology, 16(5), 1998, pp. 1743-1751
37. COLE BF; GELBER RD; KIRKWOOD JM
    SURVIVAL BENEFIT IN MELANOMA
    Journal of clinical oncology
    
    B.F. Cole et al., "SURVIVAL BENEFIT IN MELANOMA", Journal of clinical oncology, 16(1), 1998, pp. 388-389
38. MORI Y; KONDZIOLKA D; FLICKINGER JC; KIRKWOOD JM; AGARWALA S; LUNSFORD LD
    STEREOTACTIC RADIOSURGERY FOR CEREBRAL METASTATIC MELANOMA - FACTORS AFFECTING LOCAL DISEASE-CONTROL AND SURVIVAL
    International journal of radiation oncology, biology, physics
    
    Y. Mori et al., "STEREOTACTIC RADIOSURGERY FOR CEREBRAL METASTATIC MELANOMA - FACTORS AFFECTING LOCAL DISEASE-CONTROL AND SURVIVAL", International journal of radiation oncology, biology, physics, 42(3), 1998, pp. 581-589
39. KIRKWOOD JM
    ADJUVANT IFN-ALPHA-2 THERAPY OF MELANOMA
    Lancet
    
    J.M. Kirkwood, "ADJUVANT IFN-ALPHA-2 THERAPY OF MELANOMA", Lancet, 351(9120), 1998, pp. 1901-1903
40. Logan, TF; Banner, B; Rao, U; Ernstoff, MS; Wolmark, N; Whiteside, TL; Miketic, L; Kirkwood, JM
    Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY
    
    T.F. Logan et al., "Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy", CLIN EXP IM, 114(3), 1998, pp. 347-354
41. LOGAN TF; GOODING WE; WHITESIDE TL; ERNSTOFF MS; KAPLAN SS; MIKETIC L; VLOCK DR; TOMPKINS C; WOOD DL; NADLER PI; KIRKWOOD JM
    BIOLOGIC RESPONSE MODULATION BY TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) IN A PHASE IB TRIAL IN CANCER-PATIENTS
    Journal of immunotherapy with emphasis on tumor immunology
    
    T.F. Logan et al., "BIOLOGIC RESPONSE MODULATION BY TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) IN A PHASE IB TRIAL IN CANCER-PATIENTS", Journal of immunotherapy with emphasis on tumor immunology, 20(5), 1997, pp. 387-398
42. KIRKWOOD JM; BRYANT J; SCHILLER JH; OKEN MM; BORDEN EC; WHITESIDE TL
    IMMUNOMODULATORY FUNCTION OF INTERFERON-GAMMA IN PATIENTS WITH METASTATIC MELANOMA - RESULTS OF A PHASE II-B TRIAL IN SUBJECTS WITH METASTATIC MELANOMA, ECOG STUDY E-4987
    Journal of immunotherapy with emphasis on tumor immunology
    
    J.M. Kirkwood et al., "IMMUNOMODULATORY FUNCTION OF INTERFERON-GAMMA IN PATIENTS WITH METASTATIC MELANOMA - RESULTS OF A PHASE II-B TRIAL IN SUBJECTS WITH METASTATIC MELANOMA, ECOG STUDY E-4987", Journal of immunotherapy with emphasis on tumor immunology, 20(2), 1997, pp. 146-157
43. HILLNER BE; KIRKWOOD JM
    ECONOMIC-ANALYSES OF BENEFIT FROM INTERFERON-ALPHA-2B IN HIGH-RISK MELANOMA - TRADE-OFFS BETWEEN COMPLETENESS, SIMPLICITY AND CLARITY
    European journal of cancer
    
    B.E. Hillner e J.M. Kirkwood, "ECONOMIC-ANALYSES OF BENEFIT FROM INTERFERON-ALPHA-2B IN HIGH-RISK MELANOMA - TRADE-OFFS BETWEEN COMPLETENESS, SIMPLICITY AND CLARITY", European journal of cancer, 33(9), 1997, pp. 1345-1346
44. HILLNER BE; KIRKWOOD JM; ATKINS MB; JOHNSON ER; SMITH TJ
    ECONOMIC-ANALYSIS OF ADJUVANT INTERFERON-ALFA 2B (IFN) IN HIGH-RISK MELANOMA USING PROJECTIONS FROM ECOG (E)-1684
    European journal of cancer
    
    B.E. Hillner et al., "ECONOMIC-ANALYSIS OF ADJUVANT INTERFERON-ALFA 2B (IFN) IN HIGH-RISK MELANOMA USING PROJECTIONS FROM ECOG (E)-1684", European journal of cancer, 33, 1997, pp. 34-34
45. HILLNER BE; KIRKWOOD JM; ATKINS MB; JOHNSON ER; SMITH TJ
    ECONOMIC-ANALYSIS OF ADJUVANT INTERFERON ALFA-2B IN HIGH-RISK MELANOMA BASED ON PROJECTIONS FROM EASTERN-COOPERATIVE-ONCOLOGY-GROUP-1684
    Journal of clinical oncology
    
    B.E. Hillner et al., "ECONOMIC-ANALYSIS OF ADJUVANT INTERFERON ALFA-2B IN HIGH-RISK MELANOMA BASED ON PROJECTIONS FROM EASTERN-COOPERATIVE-ONCOLOGY-GROUP-1684", Journal of clinical oncology, 15(6), 1997, pp. 2351-2358
46. EDWARDS RP; GOODING W; LEMBERSKY BC; COLONELLO K; HAMMOND R; PARADISE C; KOWAL CD; KUNSCHNER AJ; BALDISSERI M; KIRKWOOD JM; HERBERMAN RB
    COMPARISON OF TOXICITY AND SURVIVAL FOLLOWING INTRAPERITONEAL RECOMBINANT INTERLEUKIN-2 FOR PERSISTENT OVARIAN-CANCER AFTER PLATINUM - 24-HOUR VERSUS 7-DAY INFUSION
    Journal of clinical oncology
    
    R.P. Edwards et al., "COMPARISON OF TOXICITY AND SURVIVAL FOLLOWING INTRAPERITONEAL RECOMBINANT INTERLEUKIN-2 FOR PERSISTENT OVARIAN-CANCER AFTER PLATINUM - 24-HOUR VERSUS 7-DAY INFUSION", Journal of clinical oncology, 15(11), 1997, pp. 3399-3407
47. KIRKWOOD JM; WILSON J; WHITESIDE TL; DONNELLY S; HERBERMAN RB
    PHASE IB TRIAL AT PICIBANIL (OK-432) AS AN IMMUNOMODULATOR IN PATIENTS WITH RESECTED HIGH-RISK MELANOMA
    Cancer immunology and immunotherapy
    
    J.M. Kirkwood et al., "PHASE IB TRIAL AT PICIBANIL (OK-432) AS AN IMMUNOMODULATOR IN PATIENTS WITH RESECTED HIGH-RISK MELANOMA", Cancer immunology and immunotherapy, 44(3), 1997, pp. 137-149
48. DREICER R; PROPERT KJ; KUZEL T; KIRKWOOD JM; ODWYER PJ; LOEHRER PJ
    A PHASE-II TRIAL OF EDATREXATE IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY
    American journal of clinical oncology
    
    R. Dreicer et al., "A PHASE-II TRIAL OF EDATREXATE IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY", American journal of clinical oncology, 20(3), 1997, pp. 251-253
49. KIRKWOOD JM; LEGHA SS
    ADVANCES IN THE DIAGNOSIS AND TREATMENT OF MALIGNANT-MELANOMA - INTRODUCTION
    Seminars in oncology
    
    J.M. Kirkwood e S.S. Legha, "ADVANCES IN THE DIAGNOSIS AND TREATMENT OF MALIGNANT-MELANOMA - INTRODUCTION", Seminars in oncology, 24(1), 1997, pp. 1-1
50. KIRKWOOD JM; RESNICK GD; COLE BF
    EFFICACY, SAFETY, AND RISK-BENEFIT ANALYSIS OF ADJUVANT INTERFERON ALFA-2B IN MELANOMA
    Seminars in oncology
    
    J.M. Kirkwood et al., "EFFICACY, SAFETY, AND RISK-BENEFIT ANALYSIS OF ADJUVANT INTERFERON ALFA-2B IN MELANOMA", Seminars in oncology, 24(1), 1997, pp. 16-23
51. KIRKWOOD JM; WAZER D; ROSENSTEIN M
    INTERFERON ADJUVANT THERAPY OF MELANOMA
    Cancer
    
    J.M. Kirkwood et al., "INTERFERON ADJUVANT THERAPY OF MELANOMA", Cancer, 79(9), 1997, pp. 1843-1845
52. VINE AK; WILLIS JM; JOHNSON M; MARTONYI C; MCIVER F; SNEED S; STANLEY SA; STERNBERG P; MEREDITH T; BROWN JM; AABERG T; CURTIS L; GILMAN J; CAPONE A; LIM J; SNIPES C; SWORDS R; WARD A; JARRETT WH; AARON J; BAXTER B; HAGLER W; THOMPSON K; SCHACHAT AP; DOLL W; ALEXANDER MF; GREENBERG EF; KAISER S; SACKETT C; TORANO JE; CAIN D; EMMERT D; GEORGE T; GOLDBERG MF; POLLACK L; RICE TA; HARTNETT M; DEMPSEY K; LICHTERMAN S; PRESEREN D; NOVAK MA; ROWE P; SINGERMAN L; ZEGARRA H; TREMPE C; NIES ZF; DUKER J; IMMERMAN R; NASRALLAH F; ODAY T; ROSENBLUM A; WEBER C; WEITER J; JAMPOL LM; PUKLIN J; CHIAPETTA B; DAUBERT G; MANSFIELD M; BEZINOVICH N; CAMPBELL A; GERTY J; GIESE M; MYERS W; PARQUE K; SCHROEDER R; WEINBERG D; GUTMAN FA; ZAKOV N; KISS T; FROBERG D; HARTE B; TANNER V; ABRAM R; AMBLER J; BERLIN L; DALEY G; ROSS D; DAVIDORF FH; TAYLOR C; BILDSTEN J; CORNETET S; CHAMBERS R; CLARK M; SHORTLIDGE G; FULLER D; ANDERSON T; AGUADO H; BRADFORD R; CONWAY D; DALRYMPLE D; EVANS R; FISH GE; NORK C; PICCHIOTTINO R; ROSE K; SNYDER W; STRAACH R; DUTTON JJ; PEDDLE K; HESTON M; LYONS C; SCHUH B; BENETZ BA; SCHIRMER R; RUIZ RS; VARGAS D; DELAGARZA M; JOHNSON R; KOHN W; MAROLA G; TRIPLETT G; HARWOOD H; HORTON T; KELLAWAY J; LAMBERT M; PRAGER T; SHETLAR D; SMITH B; STALLMAN J; WEINGEIST TA; FOUNTAIN C; GRIFFIN M; BLODI C; BOLDT HC; FISHER T; HEFFRON E; OSSOINIG K; STONE E; VERDICK R; WARNER L; MURPHREE AL; LIGGETT P; RYAN SJ; WALONKER AF; PADILLA M; QUILLENTHOMAS B; ALTOMONTE M; DELGADO S; DIDDIE K; FRAMBACH D; GREEN R; JOHNSON J; ROZIER M; SINGER M; TETREAULT G; STRAATSMA BR; CALDWELL R; BARANICK K; HASLOP M; PINAIRE B; ALLEN D; CHUN M; ENGSTROM R; GREENSPAN J; SULIT H; THAYER D; WYNBRANDT L; CHANDRA SR; LEWIS B; BLATZ M; MILLER J; STEWART L; HARRISON R; KNUTSON G; MYERS F; NEIDER M; QUACKENBOSS D; SOMERS G; STEVENS T; FINGER PT; PACKER S; PEARLBERG C; MCCRAY M; TULLER R; MURRAY TG; OLSEN KR; CICCIARELLI N; CASTELLANOS M; DELCALVO M; PEREZ J; SOLER A; ATTAWAY E; DEEN S; HESS D; JARRETT R; KOWAL D; LEWIS ML; LIEBETREU M; NICHOLSON D; RUBSAMEN P; MIELER WF; ABRAMS GW; REKOW SA; HELT P; LEWANDOWSKI M; NAUERTZRITCHIE M; WALTERS J; WIPPLINGER W; ABRAMSON DH; SERVODIDIO CA; BUDINGER K; MARTIN S; ROMANELLAWEIL A; MENDELSOHN M; WILKINS R; WOLFSON R; CHENOWETH RG; IRA S; LEIGH AJ; LORIMER E; ARENDS J; DREYER R; MA CL; RICE P; ZILIS J; WILSON DJ; WATZKE R; CORRADA F; EVANS M; HOLMES D; KLEIN M; FRAUNFELDER F; ROBERTSON J; TALBOT T; ROBERTSON DM; RUSZCZYK MJ; SCHUMANN M; BUETTNER H; LINK T; ROSTVOLD J; MARGHERIO RR; MITCHELL B; CUMMING K; MANATREY P; MCCURLEY S; BRIDGES C; FOX G; MURPHY P; PARK W; SOBEL J; SORENSON D; VERSTRAETEN T; DELPRIORE L; SMITH ME; GAINES M; CLARK L; SCHERRER F; CURTIS R; HART W; SCHATZ H; GUERTIN R; LAUGHLIN K; MILLER A; KELLY M; STOLARCZUK M; SIMPSON ER; FITZPATRICK P; PENNEY L; MACKIE A; CHRISTIANSON M; CONTRACTOR M; EWINGCHOW D; HAMMOND J; JAPP B; KAZDAN M; KODATI SM; MCGOWAN H; MCWHAE J; MIS A; PATON K; PAVLIN C; TANZER H; HAWKINS BS; DIENERWEST M; MOY CS; MARKOWITZ JA; CHURCH RY; BELONGIE CE; COATES TC; CONNOR PB; DAVIS AC; GOLDSBOROUGH IL; GRUBB SC; HARPER DM; JAMES PA; JEFFREYS WS; KEENAN JL; KERMAN JS; MELIA BM; NEWHOUSE MM; OPTICAN DC; BYRNE SF; COMELLA M; MORENO J; SUPERFINERIVERA P; DIBERNARDO C; GENDRON EK; HUGHES JR; MONTAGUE PR; ANDERSON D; SMITH L; STRAUSS J; BENNETT S; FOLK JC; FINE SL; MCCAFFREY L; REICH AM; FATULA E; NIDO V; ALBERT DM; EARLE JD; HANSON WF; KIRKWOOD JM; KURINIJ N; MCCAFFERY L; BRANDON S; GRIZZARD S; MCCORMICK B; MINTURN JT; PAYNE D; SHOFNER JM
    MORTALITY IN PATIENTS WITH SMALL CHOROIDAL MELANOMA - COMS-REPORT-NO-4
    Archives of ophthalmology
    
    A.K. Vine et al., "MORTALITY IN PATIENTS WITH SMALL CHOROIDAL MELANOMA - COMS-REPORT-NO-4", Archives of ophthalmology, 115(7), 1997, pp. 886-893
53. RABINOWICH H; BANKS M; REICHERT TE; LOGAN TF; KIRKWOOD JM; WHITESIDE TL
    EXPRESSION AND ACTIVITY OF SIGNALING MOLECULES IN T-LYMPHOCYTES OBTAINED FROM PATIENTS WITH METASTATIC MELANOMA BEFORE AND AFTER INTERLEUKIN-2 THERAPY
    Clinical cancer research
    
    H. Rabinowich et al., "EXPRESSION AND ACTIVITY OF SIGNALING MOLECULES IN T-LYMPHOCYTES OBTAINED FROM PATIENTS WITH METASTATIC MELANOMA BEFORE AND AFTER INTERLEUKIN-2 THERAPY", Clinical cancer research, 2(8), 1996, pp. 1263-1274
54. SMITH DC; GERSON SL; LIU LL; DONNELLY S; DAY R; TRUMP DL; KIRKWOOD JM
    CARMUSTINE AND STREPTOZOCIN IN REFRACTORY MELANOMA - AN ATTEMPT AT MODULATION OF O-6-ALKYLGUANINE-DNA-ALKYLTRANSFERASE
    Clinical cancer research
    
    D.C. Smith et al., "CARMUSTINE AND STREPTOZOCIN IN REFRACTORY MELANOMA - AN ATTEMPT AT MODULATION OF O-6-ALKYLGUANINE-DNA-ALKYLTRANSFERASE", Clinical cancer research, 2(7), 1996, pp. 1129-1134
55. SCHILLER JH; PUGH M; KIRKWOOD JM; KARP D; LARSON M; BORDEN E
    EASTERN COOPERATIVE GROUP TRIAL OF INTERFERON-GAMMA IN METASTATIC MELANOMA - AN INNOVATIVE STUDY DESIGN
    Clinical cancer research
    
    J.H. Schiller et al., "EASTERN COOPERATIVE GROUP TRIAL OF INTERFERON-GAMMA IN METASTATIC MELANOMA - AN INNOVATIVE STUDY DESIGN", Clinical cancer research, 2(1), 1996, pp. 29-36
56. VLOCK DR; ANDERSEN J; KALISH LA; JOHNSON JT; KIRKWOOD JM; WHITESIDE T; HERBERMAN RB; ADAMS GS; OKEN MM; HASELOW RE
    PHASE-II TRIAL OF INTERFERON-ALPHA IN LOCALLY RECURRENT OR METASTATICSQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - IMMUNOLOGICAL AND CLINICAL CORRELATES
    Journal of immunotherapy with emphasis on tumor immunology
    
    D.R. Vlock et al., "PHASE-II TRIAL OF INTERFERON-ALPHA IN LOCALLY RECURRENT OR METASTATICSQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - IMMUNOLOGICAL AND CLINICAL CORRELATES", Journal of immunotherapy with emphasis on tumor immunology, 19(6), 1996, pp. 433-442
57. WANG YP; RAO U; MASCARI R; RICHARDS TJ; PANSON AJ; EDINGTON HD; SHIPESPOTLOE JM; DONNELLY SS; KIRKWOOD JM; BECKER D
    MOLECULAR ANALYSIS OF MELANOMA PRECURSOR LESIONS
    Cell growth & differentiation
    
    Y.P. Wang et al., "MOLECULAR ANALYSIS OF MELANOMA PRECURSOR LESIONS", Cell growth & differentiation, 7(12), 1996, pp. 1733-1740
58. MAEURER MJ; STORKUS WJ; KIRKWOOD JM; LOTZE MT
    NEW TREATMENT OPTIONS FOR PATIENTS WITH MELANOMA - REVIEW OF MELANOMA-DERIVED T-CELL EPITOPE-BASED PEPTIDE VACCINES
    Melanoma research
    
    M.J. Maeurer et al., "NEW TREATMENT OPTIONS FOR PATIENTS WITH MELANOMA - REVIEW OF MELANOMA-DERIVED T-CELL EPITOPE-BASED PEPTIDE VACCINES", Melanoma research, 6(1), 1996, pp. 11-24
59. COLE BF; GELBER RD; KIRKWOOD JM; GOLDHIRSCH A; BARYLAK E; BORDEN E
    QUALITY-OF-LIFE - ADJUSTED SURVIVAL ANALYSIS OF INTERFERON ALFA-2B ADJUVANT TREATMENT OF HIGH-RISK RESECTED CUTANEOUS MELANOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY
    Journal of clinical oncology
    
    B.F. Cole et al., "QUALITY-OF-LIFE - ADJUSTED SURVIVAL ANALYSIS OF INTERFERON ALFA-2B ADJUVANT TREATMENT OF HIGH-RISK RESECTED CUTANEOUS MELANOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY", Journal of clinical oncology, 14(10), 1996, pp. 2666-2673
60. KIRKWOOD JM; STRAWDERMAN MH; ERNSTOFF MS; SMITH TJ; BORDEN EC; BLUM RH
    INTERFERON ALFA-2B ADJUVANT THERAPY OF HIGH-RISK RESECTED CUTANEOUS MELANOMA - THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP TRIAL EST 1684
    Journal of clinical oncology
    
    J.M. Kirkwood et al., "INTERFERON ALFA-2B ADJUVANT THERAPY OF HIGH-RISK RESECTED CUTANEOUS MELANOMA - THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP TRIAL EST 1684", Journal of clinical oncology, 14(1), 1996, pp. 7-17
61. KIRKWOOD JM
    THE DEVELOPMENTAL RATE OF EUPHAUSIA-CRYSTALLOROPHIAS LARVAE IN ELLIS FJORD, VESTFOLD HILLS, ANTARCTICA
    Polar biology
    
    J.M. Kirkwood, "THE DEVELOPMENTAL RATE OF EUPHAUSIA-CRYSTALLOROPHIAS LARVAE IN ELLIS FJORD, VESTFOLD HILLS, ANTARCTICA", Polar biology, 16(7), 1996, pp. 527-530
62. LOGAN TF; GOODING W; KIRKWOOD JM; SHADDUCK RK
    TUMOR-NECROSIS-FACTOR ADMINISTRATION IS ASSOCIATED WITH INCREASED ENDOGENOUS PRODUCTION OF M-CSF AND G-CSF HUT NOT GM-CSF IN HUMAN CANCER-PATIENTS
    Experimental hematology
    
    T.F. Logan et al., "TUMOR-NECROSIS-FACTOR ADMINISTRATION IS ASSOCIATED WITH INCREASED ENDOGENOUS PRODUCTION OF M-CSF AND G-CSF HUT NOT GM-CSF IN HUMAN CANCER-PATIENTS", Experimental hematology, 24(1), 1996, pp. 49-53
63. DOW AI; SHAFER SA; KIRKWOOD JM; MASCARI RA; WAGGONER AS
    AUTOMATIC MULTIPARAMETER FLUORESCENCE IMAGING FOR DETERMINING LYMPHOCYTE PHENOTYPE AND ACTIVATION STATUS IN MELANOMA TISSUE-SECTIONS
    Cytometry
    
    A.I. Dow et al., "AUTOMATIC MULTIPARAMETER FLUORESCENCE IMAGING FOR DETERMINING LYMPHOCYTE PHENOTYPE AND ACTIVATION STATUS IN MELANOMA TISSUE-SECTIONS", Cytometry, 25(1), 1996, pp. 71-81
64. ELKASSAS H; KIRKWOOD JM
    ADJUVANT APPLICATION OF INTERFERONS
    Seminars in oncology
    
    H. Elkassas e J.M. Kirkwood, "ADJUVANT APPLICATION OF INTERFERONS", Seminars in oncology, 23(6), 1996, pp. 737-743
65. AGARWALA SS; KIRKWOOD JM
    POTENTIAL USES OF INTERFERON ALPHA-2 AS ADJUVANT THERAPY IN CANCER
    Annals of surgical oncology
    
    S.S. Agarwala e J.M. Kirkwood, "POTENTIAL USES OF INTERFERON ALPHA-2 AS ADJUVANT THERAPY IN CANCER", Annals of surgical oncology, 2(4), 1995, pp. 365-371
66. BROWN ML; CHARRON M; SHAH AN; LISTER J; KIRKWOOD JM; STALTERI MF
    TUMOR IMAGING WITH GA-67-CITRATE - A COST-EFFECTIVE STRATEGY
    Radiology
    
    M.L. Brown et al., "TUMOR IMAGING WITH GA-67-CITRATE - A COST-EFFECTIVE STRATEGY", Radiology, 197, 1995, pp. 385-385
67. VLOCK DR; SNYDERMAN CH; JOHNSON JT; MYERS EN; EIBLING DE; RUBIN JS; KIRKWOOD JM; DUTCHER JP; ADAMS GL
    PHASE IB TRIAL OF THE EFFECT OF PERITUMORAL AND INTRANODAL INJECTIONSOF INTERLEUKIN-2 IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OFTHE HEAD AND NECK - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP TRIAL
    Journal of immunotherapy with emphasis on tumor immunology
    
    D.R. Vlock et al., "PHASE IB TRIAL OF THE EFFECT OF PERITUMORAL AND INTRANODAL INJECTIONSOF INTERLEUKIN-2 IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OFTHE HEAD AND NECK - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP TRIAL", Journal of immunotherapy with emphasis on tumor immunology, 15(2), 1994, pp. 134-139
68. BRADFIELD HA; TAUXE WN; LEVINE G; KIRKWOOD JM; KLEIN H; MOCHIZUKI T
    IN-111 MONOCLONAL-ANTIBODY VERSUS GA-67-CITRATE AND TC-997 SC SUBTRACTION IN A PATIENT WITH MALIGNANT-MELANOMA
    Clinical nuclear medicine
    
    H.A. Bradfield et al., "IN-111 MONOCLONAL-ANTIBODY VERSUS GA-67-CITRATE AND TC-997 SC SUBTRACTION IN A PATIENT WITH MALIGNANT-MELANOMA", Clinical nuclear medicine, 19(8), 1994, pp. 703-707
69. CHANG AY; TU ZN; BRYAN GT; KIRKWOOD JM; OKEN MM; TRUMP DL
    PHASE-II STUDY OF ECHINOMYCIN IN THE TREATMENT OF RENAL-CELL CARCINOMA ECOG STUDY E2885
    Investigational new drugs
    
    A.Y. Chang et al., "PHASE-II STUDY OF ECHINOMYCIN IN THE TREATMENT OF RENAL-CELL CARCINOMA ECOG STUDY E2885", Investigational new drugs, 12(2), 1994, pp. 151-153
70. LOGAN TF; VIRJI MA; GOODING WE; BONTEMPO FA; ERNSTOFF MS; KIRKWOOD JM
    THE PATHOGENESIS OF DISSEMINATED INTRAVASCULAR COAGULATION IN SEPSIS
    JAMA, the journal of the American Medical Association
    
    T.F. Logan et al., "THE PATHOGENESIS OF DISSEMINATED INTRAVASCULAR COAGULATION IN SEPSIS", JAMA, the journal of the American Medical Association, 271(6), 1994, pp. 427-428
71. AGARWALA SS; KIRKWOOD JM
    INTERFERONS IN THE THERAPY OF SOLID TUMORS
    Oncology
    
    S.S. Agarwala e J.M. Kirkwood, "INTERFERONS IN THE THERAPY OF SOLID TUMORS", Oncology, 51(2), 1994, pp. 129-136
72. LOGAN TF; SHANNON W; BRYANT J; KANE P; WOLMARK N; POSNER M; KIRKWOOD JM; ERNSTOFF MS; FUTRELL JW; STRAW LD; IWATUSKI S; BAHNSON R
    PREPARATION OF VIABLE TUMOR-CELL VACCINE FROM HUMAN SOLID TUMORS - RELATIONSHIP BETWEEN TUMOR MASS AND CELL YIELD
    Melanoma research
    
    T.F. Logan et al., "PREPARATION OF VIABLE TUMOR-CELL VACCINE FROM HUMAN SOLID TUMORS - RELATIONSHIP BETWEEN TUMOR MASS AND CELL YIELD", Melanoma research, 3(6), 1993, pp. 451-455
73. SOMAZA S; KONDZIOLKA D; LUNSFORD LD; KIRKWOOD JM; FLICKINGER JC
    STEREOTAXIC RADIOSURGERY FOR CEREBRAL METASTATIC MELANOMA
    Journal of neurosurgery
    
    S. Somaza et al., "STEREOTAXIC RADIOSURGERY FOR CEREBRAL METASTATIC MELANOMA", Journal of neurosurgery, 79(5), 1993, pp. 661-666
74. ELDER EM; KIRKWOOD JM; WHITESIDE TL
    CHARACTERIZATION OF HUMAN NK CELLS OBTAINED FROM CANCER-PATIENTS AND CULTURED FOR ADOPTIVE IMMUNOTHERAPY
    The Journal of immunology
    
    E.M. Elder et al., "CHARACTERIZATION OF HUMAN NK CELLS OBTAINED FROM CANCER-PATIENTS AND CULTURED FOR ADOPTIVE IMMUNOTHERAPY", The Journal of immunology, 150(8), 1993, pp. 59-59
75. WHITESIDE TL; LETESSIER E; HIRABAYASHI H; VITOLO D; BRYANT J; BARNES L; SNYDERMAN C; JOHNSON JT; MYERS E; HERBERMAN RB; RUBIN J; KIRKWOOD JM; VLOCK DR
    EVIDENCE FOR LOCAL AND SYSTEMIC ACTIVATION OF IMMUNE CELLS BY PERITUMORAL INJECTIONS OF INTERLEUKIN-2 IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    Cancer research
    
    T.L. Whiteside et al., "EVIDENCE FOR LOCAL AND SYSTEMIC ACTIVATION OF IMMUNE CELLS BY PERITUMORAL INJECTIONS OF INTERLEUKIN-2 IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK", Cancer research, 53(23), 1993, pp. 5654-5662
76. WEIDMANN E; LOGAN TF; YASUMURA S; KIRKWOOD JM; TRUCCO M; WHITESIDE TL
    EVIDENCE FOR OLIGOCLONAL T-CELL RESPONSE IN A METASTASIS OF RENAL-CELL CARCINOMA RESPONDING TO VACCINATION WITH AUTOLOGOUS TUMOR-CELLS AND TRANSFER OF IN-VITRO-SENSITIZED VACCINE-DRAINING LYMPH-NODE LYMPHOCYTES
    Cancer research
    
    E. Weidmann et al., "EVIDENCE FOR OLIGOCLONAL T-CELL RESPONSE IN A METASTASIS OF RENAL-CELL CARCINOMA RESPONDING TO VACCINATION WITH AUTOLOGOUS TUMOR-CELLS AND TRANSFER OF IN-VITRO-SENSITIZED VACCINE-DRAINING LYMPH-NODE LYMPHOCYTES", Cancer research, 53(20), 1993, pp. 4745-4749